Hookipa Pharma Inc (NASDAQ:HOOK) shares saw strong trading volume on Friday . 2,912,753 shares were traded during mid-day trading, an increase of 2,370% from the previous session’s volume of 117,928 shares.The stock last traded at $8.21 and had previously closed at $6.68.
A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of NVIDIA to $200.00 and gave the company an “outperform” rating in a research note on Monday, May 13th. Bank of America raised shares of Copa from a “neutral” rating to a “buy” rating in a research note on Monday, May 13th. Leerink Swann assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They issued an “outperform” rating and a $42.00 price target on the stock. Finally, Svb Leerink assumed coverage on shares of Hookipa Pharma in a research note on Monday, May 13th. They issued an “outperform” rating and a $20.00 price target on the stock.
The business has a 50 day simple moving average of $7.80.
Hookipa Pharma (NASDAQ:HOOK) last announced its earnings results on Monday, May 20th. The company reported ($9.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($8.85). The business had revenue of $2.24 million for the quarter, compared to the consensus estimate of $0.50 million. Equities analysts forecast that Hookipa Pharma Inc will post -2.14 EPS for the current year.
In other Hookipa Pharma news, major shareholder Sofinnova Capital Vi Fcpr bought 357,142 shares of the stock in a transaction on Tuesday, April 23rd. The shares were bought at an average price of $14.00 per share, with a total value of $4,999,988.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Bros. Advisors Lp Baker bought 892,857 shares of the stock in a transaction on Tuesday, April 23rd. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $12,499,998.00. The disclosure for this purchase can be found here.
Hookipa Pharma Company Profile (NASDAQ:HOOK)
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Read More: What is a Tariff?
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.